Inflammatory Mediators in Gastrointestinal Defense and Injury

Abstract Irrespective of where ulceration occurs in the gastrointestinal tract, it is almost always associated with mucosal inflammation. The chemical mediators that coordinate inflammatory responses also have the capability to alter the resistance of the mucosa to injury. Some inflammatory mediators increase the resistance of the mucosa to injury, while others exert “ulcerogenic” effects. In this review, we provide an overview of the major inflammatory mediators that have been shown to exert effects on mucosal defense in the gastrointestinal tract. Among the inflammatory mediators discussed are the eicosanoids (prostaglandins, leukotrienes, thromboxanes), nitric oxide, neuropeptides, and cytokines (IL-1β, TNFα). Several of these mediators are considered potential therapeutic targets for the treatment of ulcerative diseases of the digestive system, and, in some cases, clinical data are available on the efficacy of such approaches.

[1]  C. Koboldt,et al.  Pharmacological analysis of cyclooxygenase-1 in inflammation. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[2]  J. Wallace,et al.  Cyclooxygenase 1 contributes to inflammatory responses in rats and mice: implications for gastrointestinal toxicity. , 1998, Gastroenterology.

[3]  M. Steinhoff,et al.  Proteinase-activated receptors: novel mechanisms of signaling by serine proteases. , 1998, American journal of physiology. Cell physiology.

[4]  S. Nikolaus,et al.  Increased secretion of pro-inflammatory cytokines by circulating polymorphonuclear neutrophils and regulation by interleukin 10 during intestinal inflammation , 1998, Gut.

[5]  M. Respondek,et al.  Selective cyclo‐oxygenase‐2 inhibitors and their influence on the protective effect of a mild irritant in the rat stomach , 1998, British journal of pharmacology.

[6]  N. Davies,et al.  Aspirin causes rapid up‐regulation of cyclo‐oxygenase‐2 expression in the stomach of rats , 1997, Alimentary pharmacology & therapeutics.

[7]  Y. Miyagi,et al.  Expression of trypsin in vascular endothelial cells , 1997, FEBS letters.

[8]  J. Wallace,et al.  Cytokines in inflammatory bowel disease , 1997, Mediators of inflammation.

[9]  J. Hoxie,et al.  Interactions of Mast Cell Tryptase with Thrombin Receptors and PAR-2* , 1997, The Journal of Biological Chemistry.

[10]  M. Kasuga,et al.  Induction of cyclooxygenase 2 in gastric mucosal lesions and its inhibition by the specific antagonist delays healing in mice. , 1997, Gastroenterology.

[11]  J. Wallace,et al.  Exacerbation of inflammation-associated colonic injury in rat through inhibition of cyclooxygenase-2. , 1996, The Journal of clinical investigation.

[12]  D. Riendeau,et al.  Characterization of Prostaglandin G/H Synthase 1 and 2 in rat, dog, monkey, and human gastrointestinal tracts. , 1996, Gastroenterology.

[13]  M. Hollenberg,et al.  Rat proteinase‐activated receptor‐2 (PAR‐2): cDNA sequence and activity of receptor‐derived peptides in gastric and vascular tissue , 1996, British journal of pharmacology.

[14]  J. Wallace,et al.  The cellular and molecular basis of gastric mucosal defense , 1996, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[15]  R. Pounder,et al.  Thrombotic vascular risk factors in inflammatory bowel disease. , 1996, Gut.

[16]  R. Langenbach,et al.  Prostaglandin synthase 2 gene disruption causes severe renal pathology in the mouse , 1995, Cell.

[17]  M. Miller,et al.  Role of inducible nitric oxide synthase expression and peroxynitrite formation in guinea pig ileitis. , 1995, Gastroenterology.

[18]  J. Wallace,et al.  Nitric oxide as a mediator of gastrointestinal mucosal injury?—Say it ain't so , 1995, Mediators of inflammation.

[19]  P. Kubes,et al.  Leukotriene C4/D4 induces P-selectin and sialyl Lewis(x)-dependent alterations in leukocyte kinetics in vivo. , 1995, Circulation research.

[20]  D. Rachmilewitz,et al.  Experimental colitis is ameliorated by inhibition of nitric oxide synthase activity. , 1995, Gut.

[21]  J. Wallace,et al.  A nitric oxide-releasing nonsteroidal anti-inflammatory drug accelerates gastric ulcer healing in rats. , 1995, Gastroenterology.

[22]  J. Esplugues,et al.  Nitric oxide and sensory afferent neurones modulate the protective effects of low-dose endotoxin on rat gastric mucosal damage. , 1995, European journal of pharmacology.

[23]  D. Hommes,et al.  Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2). , 1995, Gastroenterology.

[24]  P. Kubes,et al.  Excess nitric oxide does not cause cellular, vascular, or mucosal dysfunction in the cat small intestine. , 1995, The American journal of physiology.

[25]  J. Wallace,et al.  Impaired vasodilatory responses in the gastric microcirculation of anesthetized rats with secondary biliary cirrhosis. , 1995, Gastroenterology.

[26]  C. Hogaboam,et al.  The selective beneficial effects of nitric oxide inhibition in experimental colitis. , 1995, The American journal of physiology.

[27]  F. Casellas,et al.  Effects of thromboxane synthase inhibition on in vivo release of inflammatory mediators in chronic ulcerative colitis. , 1995, European journal of gastroenterology & hepatology.

[28]  C. Dinarello,et al.  The interleuldn-1 family: 10 years of discovery’ , 2004 .

[29]  B. Soper,et al.  Nitric oxide synthase induction and cytoprotection of rat gastric mucosa from injury by ethanol. , 1994, Canadian journal of physiology and pharmacology.

[30]  J. Wallace,et al.  Novel nonsteroidal anti-inflammatory drug derivatives with markedly reduced ulcerogenic properties in the rat. , 1994, Gastroenterology.

[31]  A. Morelli,et al.  Pentoxifylline prevents indomethacin induced acute gastric mucosal damage in rats: role of tumour necrosis factor alpha. , 1994, Gut.

[32]  J. Wallace,et al.  A diclofenac derivative without ulcerogenic properties. , 1994, European journal of pharmacology.

[33]  J. Wallace,et al.  Mast cell activation augments gastric mucosal injury through a leukotriene-dependent mechanism. , 1994, The American journal of physiology.

[34]  F. Calzetti,et al.  Interleukin 10 (IL-10) upregulates IL-1 receptor antagonist production from lipopolysaccharide-stimulated human polymorphonuclear leukocytes by delaying mRNA degradation , 1994, The Journal of experimental medicine.

[35]  J. Wallace,et al.  Nitric oxide synthesis inhibition increases epithelial permeability via mast cells. , 1994, The American journal of physiology.

[36]  T. Macdonald,et al.  Location of tumour necrosis factor alpha by immunohistochemistry in chronic inflammatory bowel disease. , 1993, Gut.

[37]  J. Stamler,et al.  Peroxynitrite-induced rat colitis--a new model of colonic inflammation. , 1993, Gastroenterology.

[38]  K. Rajewsky,et al.  Interleukin-10-deficient mice develop chronic enterocolitis , 1993, Cell.

[39]  J. Wallace,et al.  Modulation of rat mast cell reactivity by IL-1 beta. Divergent effects on nitric oxide and platelet-activating factor release. , 1993, Journal of immunology.

[40]  P. Kubes,et al.  Nitric oxide syni hesis inhibition induces leukocyte adhesion via superoxid and mast cells , 2004 .

[41]  L. McIntire,et al.  Molecular determinants of aspirin-induced neutrophil adherence to endothelial cells. , 1993, Gastroenterology.

[42]  J. Wallace,et al.  Prostaglandin modulation of the gastric vasculature and mucosal integrity in cirrhotic rats. , 1993, The American journal of physiology.

[43]  F. S. Becker,et al.  Regulation of neutrophil-derived IL-8: the role of prostaglandin E2, dexamethasone, and IL-4. , 1993, Journal of immunology.

[44]  G. Striker,et al.  Insulin uptake and processing by cultured mouse glomerular endothelial cells. , 1993, The American journal of physiology.

[45]  C. Hawkey,et al.  Enhanced gastric mucosal leukotriene B4 synthesis in patients taking non-steroidal anti-inflammatory drugs. , 1993, Gut.

[46]  Ian G. Charles,et al.  Induction of nitric oxide synthase in human chondrocytes. , 1993, Biochemical and biophysical research communications.

[47]  R. Eliakim,et al.  Intestinal epithelial cells contribute to the enhanced generation of platelet activating factor in ulcerative colitis. , 1993, Gut.

[48]  J. Wallace,et al.  Capsaicin-induced hyperemia in the stomach: possible contribution of mast cells. , 1992, The American journal of physiology.

[49]  J. Wallace,et al.  Modulation of leukocyte adhesion in rat mesenteric venules by aspirin and salicylate. , 1992, Gastroenterology.

[50]  P. Kubes,et al.  Nitric oxide modulates epithelial permeability in the feline small intestine. , 1992, The American journal of physiology.

[51]  J. Wallace,et al.  Indomethacin-induced leukocyte adhesion in mesenteric venules: role of lipoxygenase products. , 1992, The American journal of physiology.

[52]  J. Wallace,et al.  Mechanisms underlying the protective effects of interleukin 1 in experimental nonsteroidal anti-inflammatory drug gastropathy. , 1992, Gastroenterology.

[53]  S. Stephens,et al.  Tumour necrosis factor alpha in stool as a marker of intestinal inflammation , 1992, The Lancet.

[54]  J. O'flaherty,et al.  Tumor necrosis factor-alpha regulates expression of receptors for formyl-methionyl-leucyl-phenylalanine, leukotriene B4, and platelet-activating factor. Dissociation from priming in human polymorphonuclear neutrophils. , 1991, Journal of immunology.

[55]  J. Wallace,et al.  Secretagogue-specific effects of interleukin-1 on gastric acid secretion. , 1991, The American journal of physiology.

[56]  J. Wallace,et al.  Intestinal platelet-activating factor synthesis during Nippostrongylus brasiliensis infection in the rat. , 1991, Journal of lipid mediators.

[57]  M. Savage,et al.  Serum concentrations of tumour necrosis factor alpha in childhood chronic inflammatory bowel disease. , 1991, Gut.

[58]  W. MacNaughton,et al.  Mechanisms of platelet-activating factor-induced electrolyte transport in the rat jejunum. , 1991, European journal of pharmacology.

[59]  P. Kubes,et al.  Nitric oxide: an endogenous modulator of leukocyte adhesion. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[60]  C. Valeri,et al.  Thromboxane A2 induces leukotriene B4 synthesis that in turn mediates neutrophil diapedesis via CD 18 activation. , 1991, Microvascular research.

[61]  A. Dhillon,et al.  Granulomatous vasculitis in Crohn's disease. , 1991, Gastroenterology.

[62]  R. Erikson,et al.  Expression of a mitogen-responsive gene encoding prostaglandin synthase is regulated by mRNA splicing. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[63]  G. Chiappara,et al.  Effect of indomethacin on the kinetics of tumour necrosis factor alpha release and tumour necrosis factor alpha gene expression by human blood monocytes. , 1991, Pharmacological research.

[64]  R. Danner,et al.  Detection of interleukin 8 and tumor necrosis factor in normal humans after intravenous endotoxin: the effect of antiinflammatory agents , 1991, The Journal of experimental medicine.

[65]  K. Wu,et al.  Aspirin inhibits interleukin 1-induced prostaglandin H synthase expression in cultured endothelial cells. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[66]  E. Livingston,et al.  Sensory neurons mediate protective vasodilatation in rat gastric mucosa. , 1991, The American journal of physiology.

[67]  T. Peters,et al.  Experimental non-steroidal anti-inflammatory drug-induced enteropathy in the rat: similarities to inflammatory bowel disease and effect of thromboxane synthetase inhibitors. , 1990, Gut.

[68]  Y. Taché,et al.  Central action of recombinant interleukin-1 to inhibit acid secretion in rats. , 1990, Gastroenterology.

[69]  F. Snyder Platelet-activating factor and related acetylated lipids as potent biologically active cellular mediators. , 1990, The American journal of physiology.

[70]  J. Wallace,et al.  Reduction of the severity of experimental gastric and duodenal ulceration by interleukin-1 beta. , 1990, European journal of pharmacology.

[71]  J. Wallace,et al.  Role of platelet-activating factor in ischemia/reperfusion-induced leukocyte adherence. , 1990, The American journal of physiology.

[72]  J. Wallace,et al.  Platelet-activating factor mediates gastric damage induced by hemorrhagic shock. , 1990, The American journal of physiology.

[73]  J. Wallace,et al.  Effects of leukotrienes on susceptibility of the rat stomach to damage and investigation of the mechanism of action. , 1990, Gastroenterology.

[74]  R. Lavker,et al.  Substance P induces the expression of an endothelial-leukocyte adhesion molecule by microvascular endothelium. , 1990, The Journal of investigative dermatology.

[75]  W. Hsueh,et al.  Effects of in vivo 'priming' on endotoxin-induced hypotension and tissue injury. The role of PAF and tumor necrosis factor. , 1990, The American journal of pathology.

[76]  J. Wallace,et al.  An orally active inhibitor of leukotriene synthesis accelerates healing in a rat model of colitis. , 1990, The American journal of physiology.

[77]  S. Moncada,et al.  Regulation of gastric mucosal integrity by endogenous nitric oxide: interactions with prostanoids and sensory neuropeptides in the rat , 1990, British journal of pharmacology.

[78]  J. Raud Vasodilatation and inhibition of mediator release represent two distinct mechanisms for prostaglandin modulation of acute mast cell‐dependent inflammation , 1990, British journal of pharmacology.

[79]  F. Guarner,et al.  Participation of thromboxane and other eicosanoid synthesis in the course of experimental inflammatory colitis. , 1990, Gastroenterology.

[80]  G. Zimmerman,et al.  Endothelial cell-associated platelet-activating factor: a novel mechanism for signaling intercellular adhesion , 1990, The Journal of cell biology.

[81]  J. Bienenstock,et al.  Effects of platelet-activating factor on ion transport in isolated rat jejunum. , 1989, The American journal of physiology.

[82]  I. Hutcheson,et al.  Relationship between PAF-acether and thromboxane A2 biosynthesis in endotoxin-induced intestinal damage in the rat. , 1989, Prostaglandins.

[83]  R. Stead,et al.  Mast cells are closely apposed to nerves in the human gastrointestinal mucosa. , 1989, Gastroenterology.

[84]  T. Okumura,et al.  Interleukin-1 inhibits the secretion of gastric acid in rats: possible involvement of prostaglandin. , 1989, Biochemical and biophysical research communications.

[85]  L. Flohé,et al.  Leukotriene formation by human polymorphonuclear leukocytes from endogenous arachidonate. Physiological triggers and modulation by prostanoids. , 1989, Biochemical pharmacology.

[86]  R. Eliakim,et al.  Role of platelet-activating factor in ulcerative colitis. Enhanced production during active disease and inhibition by sulfasalazine and prednisolone. , 1988, Gastroenterology.

[87]  R. Macdermott Granulocytes: The culprit in ischemic damage to the intestine , 1988 .

[88]  W. Hsueh,et al.  Bowel necrosis induced by tumor necrosis factor in rats is mediated by platelet-activating factor. , 1988, The Journal of clinical investigation.

[89]  D. Remick,et al.  Prostaglandin E2 regulates macrophage-derived tumor necrosis factor gene expression. , 1988, The Journal of biological chemistry.

[90]  J. Wallace Release of platelet-activating factor (PAF) and accelerated healing induced by a PAF antagonist in an animal model of chronic colitis. , 1988, Canadian journal of physiology and pharmacology.

[91]  A. Szczeklik,et al.  The effect of six prostaglandins, prostacyclin and iloprost on generation of superoxide anions by human polymorphonuclear leukocytes stimulated by zymosan or formyl-methionyl-leucyl-phenylalanine. , 1987, Biochemical pharmacology.

[92]  W. Hsueh,et al.  Platelet‐activating factor: an endogenous mediator for bowel necrosis in endotoxemia , 1987, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[93]  J. Wallace,et al.  Evidence for platelet-activating factor as a mediator of endotoxin-induced gastrointestinal damage in the rat. Effects of three platelet-activating factor antagonists. , 1987, Gastroenterology.

[94]  H. Kaufmann,et al.  Nonsteroidal anti-inflammatory drugs activate quiescent inflammatory bowel disease. , 1987, Annals of internal medicine.

[95]  C. Hawkey,et al.  Gastric mucosal protection with selective inhibition of thromboxane synthesis. , 1987, Gut.

[96]  R. Stead,et al.  Intestinal mucosal mast cells in normal and nematode-infected rat intestines are in intimate contact with peptidergic nerves. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[97]  C. Hawkey Synthesis of prostaglandin E2, thromboxane B2 and prostaglandin catabolism in gastritis and gastric ulcer. , 1986, Gut.

[98]  J. D. Albert,et al.  Shock and tissue injury induced by recombinant human cachectin. , 1986, Science.

[99]  W. Hsueh,et al.  Release of leukotriene C4 by isolated, perfused rat small intestine in response to platelet-activating factor. , 1986, The Journal of clinical investigation.

[100]  J. Larrick,et al.  Regulation of macrophage tumor necrosis factor production by prostaglandin E2. , 1986, Biochemical and biophysical research communications.

[101]  J. Wallace,et al.  Picomole doses of platelet-activating factor predispose the gastric mucosa to damage by topical irritants. , 1986, Prostaglandins.

[102]  J. Wallace,et al.  Potent ulcerogenic actions of platelet-activating factor on the stomach , 1986, Nature.

[103]  S. Kunkel,et al.  Prostaglandins as endogenous mediators of interleukin 1 production. , 1986, Journal of immunology.

[104]  C. Hawkey,et al.  Prostaglandins and the gastrointestinal mucosa: are they important in its function, disease, or treatment? , 1985, Gastroenterology.

[105]  J. Denburg,et al.  Mast cell heterogeneity: effects of neuroenteric peptides on histamine release. , 1985, Journal of immunology.

[106]  B. Whittle,et al.  Gastric vasoconstrictor actions of leukotriene C4, PGF2 alpha, and thromboxane mimetic U-46619 on rat submucosal microcirculation in vivo. , 1985, The American journal of physiology.

[107]  S. Kunkel,et al.  Arachidonic acid metabolites regulate interleukin-1 production. , 1985, Biochemical and biophysical research communications.

[108]  A. Ayalon,et al.  The apical surface of canine chief cell monolayers resists H+ back-diffusion , 1985, Nature.

[109]  W. Stenson,et al.  Enhanced synthesis of leukotriene B4 by colonic mucosa in inflammatory bowel disease. , 1984, Gastroenterology.

[110]  J. Salmon,et al.  The source of thromboxane and prostaglandins in experimental inflammation , 1983, British journal of pharmacology.

[111]  W. Hsueh,et al.  Experimental model of ischemic bowel necrosis. The role of platelet-activating factor and endotoxin. , 1983, The American journal of pathology.

[112]  K. Freund,et al.  Inhibition of the n-formylmethionyl-leucyl-phenylalanine induced respiratory burst in human neutrophils by adrenergic agonists and prostaglandins of the E series. , 1981, Canadian journal of physiology and pharmacology.

[113]  S. Moncada,et al.  Vasoconstriction with thromboxane A2 induces ulceration of the gastric mucosa , 1981, Nature.

[114]  J. Vane,et al.  Inhibition of Prostaglandin Synthetase in Brain explains the Anti-pyretic Activity of Paracetamol (4-Acetamidophenol) , 1972, Nature.

[115]  J. Vane,et al.  Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. , 1971, Nature: New biology.

[116]  M. Goldman,et al.  Interleukin-10 as a regulatory cytokine induced by cellular stress: molecular aspects. , 1998, International reviews of immunology.

[117]  M. Kodama,et al.  Effects of a thromboxane A2 receptor antagonist in an animal model of inflammatory bowel disease. , 1997, Digestion.

[118]  C. Sternini,et al.  Action of sensory neurons in an experimental at colitis model of injury and repair. , 1996, The American journal of physiology.

[119]  J. Wallace,et al.  Tumor necrosis factor mediation of NSAID-induced gastric damage: role of leukocyte adherence. , 1996, The American journal of physiology.

[120]  W. Hsueh,et al.  Role of leukocyte beta 2-integrin in PAF-induced shock and intestinal injury. , 1996, The American journal of physiology.

[121]  J. Wallace,et al.  Markedly reduced intestinal toxicity of a diclofenac derivative. , 1994, Life sciences.

[122]  E. Lakatta,et al.  Regulation of intracellular free Mg2+ and contraction in single adult mammalian cardiac myocytes. , 1994, The American journal of physiology.

[123]  L. Buéno,et al.  Platelet-activating factor and interleukin 1 are involved in colonic dysmotility in experimental colitis in rats. , 1993, Gastroenterology.

[124]  B. C. Chin,et al.  Prostaglandins inhibit inflammatory mediator release from rat mast cells. , 1993, Gastroenterology.

[125]  J. Wallace Gastric ulceration: critical events at the neutrophil--endothelium interface. , 1993, Canadian journal of physiology and pharmacology.

[126]  N. Lam,et al.  Helicobacter pylori and peptic ulcer disease. , 1993, Clinical pharmacy.

[127]  W. Xie,et al.  Mitogen‐inducible prostaglandin G/H synthase: A new target for nonsteroidal antiinflammatory drugs , 1992 .

[128]  J. Wallace,et al.  Pathogenesis of NSAID gastropathy: are neutrophils the culprits? , 1992, Trends in pharmacological sciences.

[129]  J. Wallace,et al.  Mechanisms underlying the protective effects of interleukin-1 in experimental NSAID-gastropathy. , 1992 .

[130]  J. Wallace,et al.  Exacerbation of experimental colitis by nonsteroidal anti-inflammatory drugs is not related to elevated leukotriene B4 synthesis. , 1992, Gastroenterology.

[131]  N. Ling,et al.  Interleukin-1 inhibits stress-induced gastric erosion in rats. , 1991, Life sciences.

[132]  W. R. Zhang,et al.  Interleukin-1 is cytoprotective, antisecretory, stimulates PGE2 synthesis by the stomach, and retards gastric emptying. , 1991, Life sciences.

[133]  E. Masini,et al.  Nitric Oxide: A Regulatory Mediator of Mast Cell Reactivity , 1991 .

[134]  G. Feuerstein,et al.  Neuropeptide Y upregulates the adhesiveness of human endothelial cells for leukocytes. , 1991, Circulation research.

[135]  P. Kubes,et al.  Platelet-activating factor-induced microvascular dysfunction: role of adherent leukocytes. , 1990, The American journal of physiology.

[136]  T. Theoharides,et al.  Mast cells: the immune gate to the brain. , 1990, Life sciences.

[137]  J. Wallace,et al.  Endothelium-derived relaxing factor (nitric oxide) has protective actions in the stomach. , 1989, Life sciences.

[138]  J. Wallace,et al.  Inhibition of leukotriene synthesis markedly accelerates healing in a rat model of inflammatory bowel disease. , 1989, Gastroenterology.

[139]  J. Wallace,et al.  Assessment of the role of platelet-activating factor in an animal model of inflammatory bowel disease. , 1989, Journal of lipid mediators.

[140]  C. Nast,et al.  In vivo production of leukotriene B4 and leukotriene C4 in rabbit colitis. Relationship to inflammation. , 1987, Gastroenterology.

[141]  W. Stenson,et al.  Metabolism of arachidonic acid in acetic acid colitis in rats. Similarity to human inflammatory bowel disease. , 1985, Gastroenterology.

[142]  A. Robert Antisecretory, antiulcer, cytoprotective and diarrheogenic properties of prostaglandins. , 1976, Advances in prostaglandin and thromboxane research.

[143]  W. Hsueh,et al.  Release of Leukotriene C 4 by Isolated , Perfused Rat Small Intestine in Response to Platelet-activating Factor , 2022 .

[144]  M. Zanetti,et al.  Inhibition by prostaglandins of leukotriene B 4 release from activated neutrophils ( chemotaxis / degranulation / superoxide / inflammation , 2022 .